Program Description
IgA nephropathy (IgAN) is a progressive disease that can lead to significant kidney damage. With new therapies now available and more on the horizon, staying current on the latest clinical guidance is essential for managed care professionals and pharmacists. This webinar addresses the rapidly changing treatment landscape for IgAN and its impact on patient care and managed care decision-making. Specifically, the focus of this webinar will be on the most updated guideline recommendations for IgAN management, as well as how they inform formulary decision making. Expert faculty will discuss the latest clinical evidence, challenges associated with current treatments, and the overarching goals of therapy. Key discussion points for managed care professionals will include strategies to improve patient access to newer therapies.
Target audience: Managed Care Pharmacist
Type of activity: Application
Release date: October 31, 2025
Expiration date: October 31, 2026
Time to complete activity: 1.0 hours
Learner level: Foundational
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Explain the pathophysiology of IgA nephropathy (IgAN), its clinical and economic burden, and the importance of implementing care pathways that support early diagnosis and intervention
- Analyze updated KDIGO guideline recommendations for IgAN management, including key treatment goals and the disease-specific relevance of proteinuria
- Explore managed care strategies, including considerations for formulary decision making, to ensure patient access to new and emerging IgAN therapies
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here